What next for newly diagnosed glioblastoma?

Evidio Domingo-Musibay, Evanthia Galanis

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune™) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.

Original languageEnglish (US)
Pages (from-to)3273-3283
Number of pages11
JournalFuture Oncology
Volume11
Issue number24
DOIs
StatePublished - Dec 1 2015

Fingerprint

temozolomide
Glioblastoma
Oncolytic Virotherapy
Equipment and Supplies
Investigational Therapies
Angiogenesis Inhibitors
Survival
Chemoradiotherapy
Standard of Care
Brain Neoplasms
Immunotherapy
Therapeutics
Clinical Trials
Pharmaceutical Preparations

Keywords

  • bevacizumab
  • glioblastoma
  • newly diagnosed
  • novo-TTF
  • radiation therapy
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

What next for newly diagnosed glioblastoma? / Domingo-Musibay, Evidio; Galanis, Evanthia.

In: Future Oncology, Vol. 11, No. 24, 01.12.2015, p. 3273-3283.

Research output: Contribution to journalArticle

Domingo-Musibay, Evidio ; Galanis, Evanthia. / What next for newly diagnosed glioblastoma?. In: Future Oncology. 2015 ; Vol. 11, No. 24. pp. 3273-3283.
@article{8c6e54591fd54e0db50e6480d75f3100,
title = "What next for newly diagnosed glioblastoma?",
abstract = "Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune™) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.",
keywords = "bevacizumab, glioblastoma, newly diagnosed, novo-TTF, radiation therapy, temozolomide",
author = "Evidio Domingo-Musibay and Evanthia Galanis",
year = "2015",
month = "12",
day = "1",
doi = "10.2217/fon.15.258",
language = "English (US)",
volume = "11",
pages = "3273--3283",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "24",

}

TY - JOUR

T1 - What next for newly diagnosed glioblastoma?

AU - Domingo-Musibay, Evidio

AU - Galanis, Evanthia

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune™) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.

AB - Glioblastoma is the most common primary brain tumor in adults. Despite current multimodality treatment including surgical resection and temozolomide-based chemoradiotherapy, median survival is only 14-16 months. Characterization of molecular alterations in glioblastoma has identified prognostic subgroups and therapeutic opportunities for clinical trials across glioblastoma subsets. Following a number of negative Phase III trials testing temozolomide dose intensification and angiogenesis inhibition, recent interim analysis data indicate survival prolongation with use of a device (Optune™) delivering alternating electrical field therapy in newly diagnosed glioblastoma patients. In this review, we present an overview of the data supporting the current standard of care and discuss novel experimental therapies in early and late phase clinical testing including devices, small molecule drugs, angiogenesis inhibitors, oncolytic virotherapy and immunotherapy.

KW - bevacizumab

KW - glioblastoma

KW - newly diagnosed

KW - novo-TTF

KW - radiation therapy

KW - temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84948949955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948949955&partnerID=8YFLogxK

U2 - 10.2217/fon.15.258

DO - 10.2217/fon.15.258

M3 - Article

VL - 11

SP - 3273

EP - 3283

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 24

ER -